What is the official website of MSD Netherlands ?

The official website of MSD Netherlands is http://www.msd.nl.

What is MSD Netherlands's cybersecurity risk score?

MSD Netherlands has an AI-generated cybersecurity risk score of 760 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has MSD Netherlands experienced?

According to Rankiteo, MSD Netherlands currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has MSD Netherlands been affected by any supply chain cyber incidents ?

According to Rankiteo, MSD Netherlands has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does MSD Netherlands have SOC 2 Type 1 certification ?

According to Rankiteo, MSD Netherlands is not certified under SOC 2 Type 1.

Does MSD Netherlands have SOC 2 Type 2 certification ?

According to Rankiteo, MSD Netherlands does not hold a SOC 2 Type 2 certification.

Does MSD Netherlands comply with GDPR ?

According to Rankiteo, MSD Netherlands is not listed as GDPR compliant.

Does MSD Netherlands have PCI DSS certification ?

According to Rankiteo, MSD Netherlands does not currently maintain PCI DSS compliance.

Does MSD Netherlands comply with HIPAA ?

According to Rankiteo, MSD Netherlands is not compliant with HIPAA regulations.

Does MSD Netherlands have ISO 27001 certification ?

According to Rankiteo,MSD Netherlands is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does MSD Netherlands operate in ?

MSD Netherlands operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does MSD Netherlands have ?

MSD Netherlands employs approximately 1,436 people worldwide.

Does MSD Netherlands own any subsidiaries ?

MSD Netherlands presently has no subsidiaries across any sectors.

How many LinkedIn followers does MSD Netherlands have ?

MSD Netherlands's official LinkedIn profile has approximately 41,795 followers.

What is the NAICS classification code for MSD Netherlands ?

MSD Netherlands is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does MSD Netherlands have a Crunchbase profile ?

No, MSD Netherlands does not have a profile on Crunchbase.

Does MSD Netherlands have a LinkedIn profile ?

Yes, MSD Netherlands maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/msd-netherlands.

How many cybersecurity incidents has MSD Netherlands experienced ?

As of August 8, 2026, Rankiteo reports that MSD Netherlands has not experienced any cybersecurity incidents.

How many peer or competitor companies does MSD Netherlands have ?

MSD Netherlands has an estimated 5,727 peer or competitor companies worldwide.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

MSD Netherlands

Boost Score +25 with badge (5 left)

760

/1000

Fair

785

/1000

Fair

MSD Netherlands Vendor Cyber Rating & Cyber Score

msd.nl

Add Your Compliance Badge

MSD – zorgen voor gezondheid Je gezondheid heeft aandacht nodig. Bescherming en zorg. Samen met zorgverleners, beleidsmakers en verzekeraars zijn wij er om je daarmee te steunen. Wij zijn MSD. We bieden patiënten én zorgverleners innovatieve geneesmiddelen die het verschil kunnen maken tussen ziek op bed liggen én de gewone, dagelijkse dingen doen. Soms zelfs tussen leven en dood. Wij zijn actief op tal van gebieden. En zoeken continu nieuwe oplossingen voor ziektes waar nog geen antwoord op is. Altijd met aandacht voor de juiste patiënt op het juiste moment. We ontwikkelen ook slimme oplossingen om medicatie optimaal in te zetten. Zodat we mensen helpen en tegelijkertijd verspilling tegengaan. Waardoor geneesmiddelen effectiever,

MSD Netherlands A.I CyberSecurity Scoring

Scoring History

MSD Netherlands

MSD Netherlands CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

MSD Netherlands Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for MSD Netherlands

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for MSD Netherlands in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for MSD Netherlands in 2026.

Incident Types MSD Netherlands vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for MSD Netherlands in 2026.

Incident History - MSD Netherlands (X = Date, Y = Severity)

Loading…

SUBSIDIARY

MSD Netherlands Subsidiaries

Parent Company

MSD Netherlands

Pharmaceutical Manufacturing

Website: http://www.msd.nl

Company Size: 1,001-5,000 employees

No subsidiary data available for this company.

Loading…

MSD Netherlands Similar Companies

Johnson & Johnson Innovative Medicine

cb jnj.com

At Johnson & Johnson Innovative Medicine, we innovate with purpose, to lead where medicine is going. The experiences of patients around the world inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science with compassion, we confidently address the most complex diseases of our time and develop the potential medicines of tomorrow. We are continuously working to develop treatments, aspiring to find cures, pioneering the path from lab to life, and championing patients every step of the way. https://bit.ly/3reuMvK

Hikma Pharmaceuticals

cb hikma.com

For almost 50 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 800* high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing plants, 3 R&D hubs and c9,500 employees worldwide. *As of December 2025 Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668 For all product information and enquiries, please contact us at [email protected]

Parexel

parexel.com

Parexel is a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, our 24,000+ professionals worldwide work in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind — broadening access and making clinical research a care option for anyone, anywhere. Our proven track record spans 40+ years and drives us forward, advancing clinical research in healthcare’s most complex areas while harnessing innovation to drive efficiencies across every phase of the clinical development process. Our insights-driven approach, proven delivery and trusted execution are accelerating the delivery of life-changing treatments to patients — With Heart.™ We continue to earn recognition industrywide, including the 2025 Scrip Award for “Best Contract Research Organization – Full-Service Provider,” 2024 Fierce Biotech CRO Award for "Innovative Approaches to Patient-Centric Research" and the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award. Community Guidelines Because Parexel’s social media channels are open to the general public and employees, we are not responsible for views expressed other than our own. However, we do not tolerate posts that are: • Abusive, harassing or threatening to others. • Defamatory, offensive, obscene, vulgar or depicting violence. • Hateful targeting by race/ethnicity, age, color, creed, religion, gender, sexual preference or orientation, nationality or political beliefs. • Sexually explicit or pornographic. • Fraudulent, deceptive, libelous, misleading or unlawful. • Referencing criminal or illegal activity. • Spamming. We reserve the right to remove comments that do not adhere to our guidelines and report users who violate the rules of our page.

Merck Group

merckgroup.com

This channel is not intended for U.S. and Canadian visitors. Merck operates in the U.S. and Canada as EMD Serono in Healthcare, MilliporeSigma in Life Science and EMD Electronics in Electronics. An unaffiliated and unrelated company, Merck & Co., Inc., Kenilworth, NJ, US holds the rights in the trademark MERCK in the U.S. and Canada. _______________________________ We are Merck, a leading global science and technology company headquartered in Germany. We are curious explorers, courageous pioneers, and ingenious inventors. Our colleagues across the globe love innovating with science and technology to enrich people’s lives with our solutions in Life Science, Healthcare, and Electronics. Together, we dream big and are passionate about caring for our rich mix of people, customers, patients, and the planet. We believe in the positive power of science and technology. It has determined our actions since 1668 and inspires us to continue researching for a future worth living. As a family-owned company with over 350 years of experience, we stand for sustainability, responsibility, and innovative strength. We take pride in being a diverse and inclusive company that values and fosters the talents and abilities of our employees. That's why we are always looking for curious minds that see themselves imagining the unimaginable with us. Work your Magic and join Merck. Legal Disclaimer: www.merckgroup.com/en/legal-disclaimer.html Data Privacy Declaration: www.merckgroup.com/en/privacy-statement

Lupin

lupin.com

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

Alkem Laboratories Ltd.

alkemlabs.com

A single idea, which sprouts from a human mind, contains the potential to create marvels that can influence generations. It can redefine rules, it can transform the world. Back in the year 1973, a team of individuals came with such an idea – The idea called Alkem. It was highly potent and resilient, like a spark that could ignite a thousand more ideas. And it did! Looking back at our 4 decade, illustrious journey, that one small idea has Not only triggered us to become one of India’s largest generic and specialty pharmaceutical company but also, create a foothold in over 50 countries 32% of our revenue is generated via offshore sales. As well as we have consistently been ranked amongst the top ten pharmaceutical companies in India. Our portfolio includes illustrious brands like Clavam, Pan, Pan-D and Taxim-O, which feature amongst top 50 pharmaceutical brands in India. For over a decade, our dominance in anti-infective segment has remained unchallenged. We have 21 manufacturing facilities at multiple locations in India and the United States of America. Our upper-crest facilities are inspected and audited as per cGMP guidelines as laid down by leading regulatory authorities such as USFDA, MHRA - UK, SAHPRA-South Africa, TGA - Australia, ANVISA - Brazil, WHO - Geneva, TPD - Health Canada, PPB - Kenya, NDA - Uganda, MOH - Sudan, INVIMA - Colombia, TFDA - Tanzania, Zimbabwe, BfArM-Germany & Other Africa, Asian & CIS Countries. Another feather in our cap was added on December 23rd, 2015, when, Alkem completed it's Initial Public Offering (IPO) and was listed on the Bombay Stock Exchange Limited and the National Stock Exchange of India Limited. Although passion is the fuel that keeps ideas alive, innovation is the catalyst that gives it flight! With over 500 scientists working in 5 global R&D centers, we are empowering innovations that align with our philosophy of ‘Extended Lifecare Beyond Boundaries’.

Intas Pharmaceuticals

intaspharma.com

Intas is one of the leading multinational pharmaceutical formulation development, manufacturing, and marketing organization in the world. It has been growing at 19% CAGR and crossed the $2.5 billion mark in the past financial year. The company has set up a network of subsidiaries, under the name Accord Healthcare in the EU, US, Canada, SA, Australia, APAC as well as CIS & MENA regions. Intas is present in 85+ countries, with more than 70% of its revenue coming from global business. Currently ranked 6th in the Indian pharmaceutical market, it’s the largest privately owned Indian generic pharma company. Intas has established leadership in key therapeutic segments like CNS, Cardio, Diabeto, Gastro, Urology, Oncology & Animal Health in India. We are among the top 10 generic players in the highly regulated markets of EU, US & UK. Intas operates 17 advanced formulations, R&D, and distribution facilities, of which 10 are in India and the rest in the UK, Mexico & Greece with the help of our 23,000+ Human Capital. Between them, the facilities are accredited by global regulators such as USFDA, EMA, MHRA, TGA, and others. The company invests ~6-7% of its revenues in R&D and has over 10,000 product registrations worldwide with a strategic pipeline of 300+ high-value FTF/FTM, Biosimilars, and NDDS products. Intas' highly advanced EU-GMP Certified Biopharma division is fueled by a mission to provide affordable “Biosimilars for Billions” across niche segments such as oncology, auto-immune, ophthalmology, nephrology, rheumatology, and hormone-based therapies. The Plasma Fractionation Unit of Intas Pharmaceuticals is a pioneer in manufacturing plasma-derived therapeutics. It houses a full-fledged R&D lab and a state-of-the-art WHO-GMP-certified manufacturing facility complemented with a GLP-compliant QC lab. Our values of Innovation, Customer Delight, Ownership & Collaboration, Performance Focus & Care for Society are the driving forces toward excellence.

Alembic Pharmaceuticals Limited

alembic-india.com

Established in 1907, Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates. Alembic is the market leader in the Macrolides segment of anti-infective drugs in India. Alembic's manufacturing facilities are located in Vadodara and Baddi in Himachal Pradesh. The plant at Vadodara has the largest fermentation capacity in India. The Panelav facility houses the API and formulation manufacturing (both US FDA approved) plants. The plant at Baddi, Himachal Pradesh manufactures formulations for the domestic and non-regulated export market. The company has a state of the art Research Centre at Vadodara.

UCB

cb ucb.com

At UCB, we believe everyone deserves to live the best life they can - as free as possible from the challenges and uncertainty of disease. Our purpose is to support people living with severe central nervous system and immunological conditions by delivering meaningful solutions that go beyond medicine. We are driven by the experiences of patients and caregivers, and inspired to pursue innovations that create real value - not just in clinical outcomes, but in everyday moments, dreams pursued, and simple pleasures enjoyed. Our ambition is to unlock transformative science and technologies that respond to unmet needs and elevate lives. From our headquarters in Belgium to nearly 40 countries around the world, we nurture a culture of respect and care. By listening deeply and collaborating across borders and disciplines, we enable cutting-edge research shaped by patients’ needs. Through strong connections with healthcare professionals, partners, and communities, we strive to make a lasting impact - today and into the future. We're inspired by patients, driven by science.

Loading…

NEWS

MSD Netherlands CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

14 companies hiring in cybersecurity right now

A round-up of the most intersting companies currently hiring in the cybersecurity sector and information about where to apply.

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-52880

SUMMARY

Klever-Go is the Go implementation of the Klever blockchain protocol. Versions from 1.7.14 through 1.7.17 are vulnerable to a remotely triggerable denial of service. Both REST APIs are started with the Gin Engine.Run convenience method, which serves requests through Go's default HTTP server with no ReadHeaderTimeout, ReadTimeout, or MaxHeaderBytes configured. As a result, incoming connections that never complete their request headers are held open indefinitely. When a REST listener is reachable beyond localhost through the documented all-interface bind or a Docker port-publish deployment, a single unauthenticated client can open many slow-header connections and hold them open until server file descriptors are exhausted, preventing the API from accepting new connections. This renders the REST API unavailable to legitimate clients. This issue is fixed in version 1.7.18.

Published

Date2026-08-07

Updated

Date2026-08-07

RISK INFORMATION (Score: 7.5)

cvss3

Base Score: 7.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

3.9

REFERENCES

CVE-2026-52879

SUMMARY

Klever-Go is the Go implementation of the Klever blockchain protocol. In versions 1.7.14 through 1.7.17, the direct-message ingress handler spawns a new goroutine for every incoming direct message before the processor-level antiflood layer makes any admission decision, with no semaphore, throttler, or bound on the number of concurrent in-flight spawns. Because the antiflood check runs inside the spawned goroutine rather than before it, a single connected peer can open a direct-send stream and send a stream of well-formed messages to force unbounded goroutine creation, where each goroutine allocates its own stack and holds a message reference until processing completes, adding scheduler and garbage-collection pressure faster than the runtime can drain it. This lets one peer degrade the node's availability and its ability to process legitimate traffic, resulting in a remotely triggerable denial of service. The issue is fixed in 1.7.18.

Published

Date2026-08-07

Updated

Date2026-08-07

RISK INFORMATION (Score: 7.5)

cvss3

Base Score: 7.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

3.9

REFERENCES

CVE-2026-52878

SUMMARY

Klever-Go is the Go implementation of the Klever blockchain protocol. Versions 1.7.14 through 1.7.17 are vulnerable to a nil-pointer panic triggered by a protobuf Transaction whose embedded RawData sub-message is omitted. This omission causes RawData to decode to nil. Every transaction gossiped on the Klever-Go P2P network is decoded and validated synchronously inside the libp2p pubsub topic-validator callback, where txVersionChecker.CheckTxVersion dereferences tx.RawData.Version with no nil check. Because the libp2p pubsub callback, the underlying go-libp2p-pubsub validation worker, and Klever's own network/p2p layer install no recover(), the panic propagates and crashes the entire node process. The attacker payload is a 3-byte protobuf message; no validator key, stake, funds, or on-chain account is required, and delivery aimed at enough of the BLS validator set can halt block production, resulting in a chain halt. This issue has been fixed in version 1.7.18.

Published

Date2026-08-07

Updated

Date2026-08-07

RISK INFORMATION (Score: 7.5)

cvss3

Base Score: 7.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

3.9

REFERENCES

CVE-2026-49343

SUMMARY

Klever-Go is the Go implementation of the Klever blockchain protocol. In versions prior to 1.7.18, the account-data trie syncers are vulnerable to a resource-exhaustion flaw that leaks bounded throttler slots on error paths. In syncDataTrie() (in both userAccountsSyncer.go and kappAccountsSyncer.go), StartProcessing() reserves a slot from the NumGoRoutinesThrottler, but the corresponding EndProcessing() is only called on the success path and on the duplicate-root early return. As a result, any error from trie.NewTrie(), trie.NewTrieSyncer(), or trieSyncer.StartSyncing() (including the network-dependent timeout path) permanently consumes one slot for the lifetime of the throttler. An attacker who can repeatedly cause trie-node sync failures or timeouts during bootstrap can exhaust the bounded throttler, after which further account-data trie syncs stop making progress and SyncAccounts() returns a timeout. Because epoch bootstrap in syncUserAccountsState() and syncKappAccountsState() aborts on any such error, this causes bootstrap to fail, a core availability issue affecting fresh, restarting, or resyncing nodes and validators. This issue is fixed in version 1.7.18.

Published

Date2026-08-07

Updated

Date2026-08-07

RISK INFORMATION (Score: 5.9)

cvss3

Base Score: 5.9

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

2.2

REFERENCES

CVE-2026-48122

SUMMARY

Ruby LSP is an implementation of the language server protocol for Ruby. Several workspace-level settings in the Ruby LSP VS Code extension prior to version 0.10.4 could override the path to the Ruby executable, the version manager executables, or the Bundler `Gemfile` used at startup. A malicious repository containing a `.vscode/settings.json` could set these values to attacker-controlled targets. Opening and trusting the repository would then execute code with the privileges of the developer. The Ruby LSP gem and clients of the language server in other editors are not affected. Version 0.10.4 of the Ruby LSP VS Code extension fixes the issue.

Published

Date2026-08-07

Updated

Date2026-08-07

RISK INFORMATION (Score: )

cvss4

Base Score: 5.4

Complexity: LOW

CVSS:4.0/AV:L/AC:L/AT:P/PR:L/UI:A/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

https://github.com/Shopify/ruby-lsp/security/advisories/GHSA-2x7g-8mp4-572w

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…